Verve Therapeutics, Inc. (VERV)
NASDAQ: VERV · Real-Time Price · USD
11.28
+0.07 (0.62%)
At close: Jul 3, 2025, 1:00 PM
11.24
-0.04 (-0.34%)
After-hours: Jul 3, 2025, 4:20 PM EDT
Verve Therapeutics Employees
Verve Therapeutics had 274 employees as of December 31, 2024. The number of employees increased by 19 or 7.45% compared to the previous year.
Employees
274
Change (1Y)
19
Growth (1Y)
7.45%
Revenue / Employee
$217,566
Profits / Employee
-$660,606
Market Cap
1.01B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 274 | 19 | 7.45% |
| Dec 31, 2023 | 255 | 51 | 25.00% |
| Dec 31, 2022 | 204 | 91 | 80.53% |
| Dec 31, 2021 | 113 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VERV News
- 14 days ago - VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV - Business Wire
- 16 days ago - Top 3 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
- 16 days ago - Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion - WSJ
- 16 days ago - Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say - Reuters
- 16 days ago - Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk - PRNewsWire
- 16 days ago - Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. - Barrons
- 17 days ago - Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - Reuters
- 4 weeks ago - Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire